Stem Cell Therapy for Multiple Sclerosis and Rheumatoid Arthritis: Scientific Rationale

Article

In this video, Dr. Neil Riordan, Founder and President of the Stem Cell Institute in Panama, discusses the scientific rationale for using adipose tissue-derived stem cells and T-regulatory cells to treat MS and rheumatoid arthritis.

In this video, Dr. Neil Riordan, Founder and President of the Stem Cell Institute in Panama, discusses the scientific rationale for using adipose tissue-derived stem cells and T-regulatory cells to treat MS and rheumatoid arthritis.

Recent Videos
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Related Content
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado

Transplant Eligibility Versus CAR-T Eligibility

Manali Kamdar, MD;Noah Stansfield
January 16th 2025
Article

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.

ImmunoLogic

CGTLive® Presents: ImmunoLogic, A Video Podcast With Joseph Fraietta, PhD

Joseph A. Fraietta, PhD;Noah Stansfield;Matt Hoffman
December 18th 2024
Podcast

Hosted by Joseph Fraietta, PhD, ImmunoLogic will be tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility.

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado

Sequencing of Treatment in Third-Line R/R LBCL

Manali Kamdar, MD;Noah Stansfield
January 15th 2025
Article

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.

Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona

The Promise of Cell Therapy Approaches in Epilepsy

Marco Meglio
December 17th 2024
Podcast

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Jonathan Parker, MD, PhD.

Verismo Therapeutics’ Trial for R/R B-NHL CAR-T SynKIR-310 Doses First Patient

Verismo Therapeutics’ Trial for R/R B-NHL CAR-T SynKIR-310 Doses First Patient

Noah Stansfield
January 14th 2025
Article

The multicenter trial is open to patients with forms of r/r B-NHL including DLBCL, FL, MCL, and MZL.

Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen

Ocugen’s Retinitis Pigmentosa Gene Therapy OCU400 Sustains or Improves Visual Function in 2-Year Follow-Up Data

Noah Stansfield
January 13th 2025
Article

Among 9 patients treated in the study who were evaluable at 2 years posttreatment, all 9 showed improved or preserved visual function in comparison to their untreated fellow eyes.

© 2025 MJH Life Sciences

All rights reserved.